Rehabilitation of reproductive health of women with menstrual cycle disorders due to chronic inflammatory diseases of the pelvic organs




menstrual disorders, chronic inflammatory diseases of the pelvic organs, phytotherapy, Normocycle


The article presents the results of the comparative study of the effectiveness of phytodrug Normocycle to restore the menstrual cycle in women with chronic inflammatory diseases of the pelvic organs.

The study cohort included 96 women aged 25–32 years with verified chronic inflammatory diseases of the pelvic organs and disorders of the menstrual cycle, which developed after suffering inflammation.

At the first phase of the rehabilitation program was provided for the appointment of a 14-day course of anti-inflammatory therapy for all study participants. Patients from two major groups received Normocycle by standard scheme: the first group (40 patients) – from the first day of anti-inflammatory therapy and for 3 months thereafter, the second group (30 patients) –

within 3 months after completion of the anti-inflammatory therapy. 26 patients of control group received anti-inflammatory therapy only.

As a result of treatment in both major clinical groups was observed significantly decrease the incidence of dysmenorrhea (from 67.5 to 12.5% in the first group and from 53.3 to 20.0% in the second group), whereas significant reduction the manifestations of dysmenorrhea in patients of control group was occurred only in 15.4% of cases (from 42.3 to 26.9%). Normalization of the menstrual cycle after 3-month Normocycle therapy was occurred in 77.5% of patients of the first group and 70.0% of patients of the second group, and only in 42.3% of cases of the comparison group.

As the study authors note, rehabilitation of reproductive function in women with menstrual cycle disorders due to inflammatory diseases of the pelvic organs should be initiated concurrently with the anti-inflammatory therapy. Pharmacological effects of Asparagus racemosus, Glycyrrhiza glabra, Kurkuma longa, Symplocos racemosa, which are the part of the drug Normocycle, enhance the effects of anti-inflammatory therapy, and allow to achieved the clinical effect in 77.5% of patients, the normalization of hormonal balance at 72.5% of patients and the recovery of ovulatory cycles in 52.9% of patients.

Author Biographies

В. І. Пирогова, Danylo Halytsky Lviv National Medical University

MD, head of the Obstetrics, Gynaecology and Perinatology Department, Faculty of Postgraduate Education

С. О. Шурпяк, Danylo Halytsky Lviv National Medical University

PhD, assistant of the Obstetrics, Gynaecology and Perinatology Department, Faculty of Postgraduate Education 


  1. Out-patient care in obstetrics and gynecology: A Practical Guide. Ed. by I.S. Sidorova, T.V. Ovsyannikova, I.O. Makarov. Moscow. MEDpress-inform (2009): 720 p.
  2. Krasnopolskyi, V.I., Serova, O.F., Tumanova, V.A., et al. “Influence of infections on women reproductive system.” Russian Gerald of obstetrician-gynecologist 4.5 (2004): 26–9.
  3. Vorona, I.G., Bergman, A.S. Hormonal homeostasis in patients with non-specific salpingoophoritis. Riga. Zinante (1990): 98 p.
  4. Gevorkyan, M.A., Manukhin, I.B., Tumilovich, L.G. Gynecologic Endocrinology Clinical lectures: a guide for physicians. 2nd ed. ext. Moscow. GEOTAR-Media (2010): 280 p.
  5. Gynecology: A Guide for Physicians. Ed. by V.N. Serov, E.F. Kira. Moscow. Litterra (2008): 840 p.
  6. Dubisskaya, L.A., Lobanova, O.V. “Regional features of the reproductive health of population.” Health Sector 4 (2009): 36–41.
  7. Islamova, G.O. “On the treatment of menstrual cycle disorders in women of reproductive age.” Women’s Health 5.91 (2014): 1–3.
  8. Kaygorodova, T.V., Vojtsekhovskaya, Z.I., Zemlyanova, E.V. “WHO’s strategic approach to reproductive health and healthy lifestyles.” Issues of economics and management for the health sector managers 5 (2007): 28.
  9. Kulaga, O.K., Demidchik, Y.E. “The role of inflammation in the formation of endocrine disorders in obstetrics and gynecology.” Reproductive health Eastern Europe 5 (2012): 121–4.
  10. Mikhalevich, S.I., Kostyuk, S.A., Ismail, M.N. Reproductive health in women with STIs. Belarus Medical Academy of postgraduate education. Minsk (2008): 360 p.
  11. WHO monographs on medicinal plants commonly used in the Newly Independent States (NIS). WHO. Geneva (2010).
  12. Prilepskaya, V.N., Yaglov, V.V. Inflammatory diseases of the pelvic organs. Moscow. GEOTAR-Media (2010): 128 p.
  13. Razumeiko, D.P., Markush, I.M. “Optimization of treatment of patients with salpingoophoritis and menstrual dysfunction in women of reproductive age.” Actual issues of pediatrics, obstetrics and gynecology 2 (2012): 184–7.
  14. Serov, V.N., Zharov, E.G. Modern aspects of the treatment of genital infection in women. Moscow. Russian Society of Obstetricians and Gynecologists (2009): 36 p.
  15. Tikhomirov, A.L., Lubnin, D.M., Yudaev, V.N. Reproductive aspects of gynecological practice. Ed. by A.L. Tikhomirov. Moscow (2002): 222 p.
  16. Tolstikov, G.A., Baltina, L.A., Grankina, V.P. Licorice: biodiversity, chemicals, used in medicine. Novosibirsk. Academic Publishing House “Geo” (2007): 311 p.
  17. Trokhimovich, O.V., Revenko, O.O. “Features of endocrine status in women with tubal-peritoneal infertility who underwent an abortion.” Pediatrics, Obstetrics and Gynecology 72.1 (2010): 78–81.
  18. Khmelnitskyi, O.K., Glukhovets, B.I. “Characteristics of hormone-immune status in inflammatory diseases of the female reproductive system.” Archive pathol 52.11 (1990): 5–9.
  19. Acharya Balkrishna. Secrets of Indian Herbs for Good Health. Divya Prakshan. Hardwar (2008): 383–386.
  20. Khare, C.P. Ayurvedic Pharmacopoeial Plant Drugs: Expanded Therapeutics. СRC Press, Taylor&Fransis Group (2016).
  21. Bhutani, K.K., Jadhav, A.N., Kalia, V.J. “Effect of Symplocos racemosa Roxb. on gonadotropin release in immature female rats and ovarian histology.” Ethnopharmacol 94.1 (2004): 197–200.
  22. Blake, D.R. “Identification of symptoms that indicate a pelvic examination is necessary to exclude PID in adolescent women.” J Pediatr Adolesc Gynecol 1.16 (2003): 25–30.
  23. Bopana, N., et al. “Asparagus racemosus – ethnopharmacological evaluation and conservation needs.” J Ethnopharmacol 110.1 (2007): 1–15.
  24. Centers for Disease Control and Prevention. Sexually Transmitted Disease Treatment Guidelines. Pelvic Inflammatory Disease. MMWR 59 (RR-12) (2010): 110 p.
  25. Furusawa, J., Funakoschi-Tago, M., Mashino, T., et al. “Glycyrriza inflana-derived chacones, Licochacone A, Licochacone B and Licochacone D, ingibit phosphrylation of NF-kappa B p62 in LPS signaling pathway.” Int Immunopharvacol 9.4 (2009): 499–507.
  26. Haggerty, C.L., Schulz, R., Ness, R.B. “Lower quality of life among women with chronic pelvic pain after pelvic inflammatory disease.” Obstet Gynecol 102.5.1 (2003): 934–6.
  27. Haggerty, C.L., Ness, R.B. “Epidemiology, pathogenesis and treatment of pelvic inflammatory disease.” Expert Rev AntiInfect Ther 4 (2006): 235–47.
  28. Hussain, S., Gaffney, J., Ahmed, N., et al. “An investigation of the kinetic and anti-angiogenic properties of plant glycoside inhibitors of thimidine phosphorylase.” J Asian Nat Prod Res 11 (2009): 159–67.
  29. Goyal, R.K., Singh, J., Lal, H. “Asparagus racemosus – an update.” Indian J Med Sci 57 (2003): 408.
  30. Gulfam Nasar, Irum Saba. “Antibacterial activity of chemical constituents isolated from Asparagus racemosus.” Bangladesh J Pharmacol 9 (2014): 1–3.
  31. Jaiyeoba, O., Lazenby, G., Soper, D.E. “Recommendations and rationale for the treatment of pelvic inflammatory disease.” Expert Rev Anti Infect Ther 9.1 (2011): 61–70.
  32. Jaiyeoba, O., Soper, D.E. “A practical approach to the diagnosis of pelvic inflammatory disease.” Infect Dis Obstet Gynecol (2011): 753037. DOI: 10.1155/2011/753037
  33. Jennings, R.T., Baker, E.S. “Gynecological and reproductive issues for women in space: a review.” Obstet Gynecol Surv 55.2 (2000): 109–16.
  34. Lindbohm, M.L. “Women’s reproductive health: some recent developments in occupational epidemiology.” Am J Ind Med 36.1 (1999): 18– 24.
  35. Lin, H.W., Tu, Y.Y., Lin, S.Y. “Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study.” Lancet Oncol 12.9 (2011): 900–4.
  36. Muhammad Abdullah Shah, Syed Muhammad Abdullah, et al. “Ethnopharmacological of curcuma longa: a review.” IJPSR 4.1 (2013): 103–12.
  37. Nagao, Y., Sata, M., Suzuki, M., et al. “Effectiveness of glycyrrhizin for oral lichen planus in patients with chronic HCV infection.” J Gastroenterol 16 (2002): 168–72.
  38. 2012 European Guideline for the Management of Pelvic Inflammatory Disease, v. 5. Available from: [], last accessed Dec 4, 2016.
  39. Pole, S. Ayurvedic Medicine: The Principles of Traditional Practice. Churchill Livingston (2006): 271–2.
  40. Raval, B.P., Patel, J.D., Patel, B.A., Ganure, A.L. “Potent in vitro anticancer activity of Symplocos racemosa bark.” Rom J Biol Plant Biol 54 (2009): 135–40.
  41. RCOG Green Top Guidelines-Management of Pelvic Inflammatory Disease (2003, 2009).
  42. Available from: [], last accessed Dec 4, 2016.
  43. Shadia, A.T. “Yassin Herbal Remedy used by Rural Adolescent girls with Menstrual Disorders.” Journal of American Science 8.1 (2012).
  44. Simms, I., Stephenson, J.M. “Pelvic inflammatory disease epidemiology: what do we know and what do we need to know.” Sex Transm Inf 76 (2000): 80–7.
  45. Sheth, S. S. “Reproductive health and obstetricians and gynecologists.” Ann NY Acad Sci 997 (2003): 1–10.
  46. Trent, M., Bass, D., Ness, R.B., Haggerty, C. “Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinicalhealth (PEACH) study.” Sex Transm Dis 38.9 (2011): 879–81.
  47. Vidyasagar, G.M., Murthy, S.M. “Siddalinga Ethnomedicinal plants used to treat menstrual disorders by tribal people in Bellary district of Karnataka.” India IJPLS 3 (2012): 1871–6.
  48. Williamson, E. Major Herbs of Ayurveda. Churchhill Livingstone (2002): 51–4.



How to Cite

Пирогова, В. І., & Шурпяк, С. О. (2016). Rehabilitation of reproductive health of women with menstrual cycle disorders due to chronic inflammatory diseases of the pelvic organs. REPRODUCTIVE ENDOCRINOLOGY, (32), 29–36.



Inflammatory diseases